Eloralintide for Obesity

This trial tests a new treatment called Eloralintide to determine its effect on the rate of stomach emptying in individuals who are overweight or obese. Researchers aim to discover if Eloralintide can aid weight management by slowing digestion. Participants will be divided into groups, with some receiving Eloralintide and others a placebo (a harmless, inactive substance). This trial may suit those who have been overweight or obese for a while and whose weight has remained stable over the past three months. As a Phase 1 trial, participants will be among the first to receive this new treatment, assisting researchers in understanding its effects on people.

Earlier studies found that Eloralintide was generally well tolerated. Research has shown that no deaths occurred during the trials, and only a small number of participants experienced serious side effects. The most common side effect was decreased appetite, affecting more than 10% of those taking Eloralintide. Other studies have found that most people did not experience severe or dangerous side effects. This suggests that Eloralintide is quite safe for humans.¹²³⁴⁵

Unlike most current obesity treatments that focus primarily on appetite suppression or calorie absorption, Eloralintide offers a unique approach by targeting metabolic pathways to enhance energy expenditure. Researchers are excited about Eloralintide because it is administered subcutaneously (SC), which can offer more consistent dosing and potentially fewer side effects compared to oral medications. Additionally, its novel mechanism may provide a new avenue for managing obesity, offering hope for those who haven't found success with existing therapies.

Studies have shown that Eloralintide, a drug targeting the amylin receptor, can significantly aid weight loss in overweight or obese individuals. Research indicates that after 48 weeks, patients lost between 9% and 20% of their weight, depending on the dose. Specifically, a 9 mg dose resulted in the highest average weight loss of 20%. This trial will include various cohorts receiving different doses of Eloralintide, along with a placebo group, which in previous studies resulted in only a 0.4% weight loss. These findings suggest that Eloralintide could be an effective option for weight management.⁴⁶⁷⁸⁹